Paper Details

  1. Home
  2. Paper Details

COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.

Author: AlexopoulosDimitrios, AngiolilloDominick J, DelewiRonak, DilettiRoberto, KrucoffMitchell W, LemmertMiguel E, MontalescotGilles, NuisRutger-Jan, ParadiesValeria, SmitsPieter C, Van MieghemNicolas M, VlachojannisGeorgios J, VogelRosanne F, WilschutJeroen M, ZijlstraFelix, van VlietRia, van der WaardenNancy

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dual antiplatelet therapy is crucial for patients with ST elevation myocardial infarction (STEMI). This review discusses the evidence suggesting that administration of crushed tablets of the P2Y<sub>12</sub> inhibitor prasugrel improves drug absorption and achieves earlier antiplatelet effects in STEMI patients undergoing primary percutaneous coronary intervention (PCI).
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND">Dual antiplatelet therapy constitutes the cornerstone of medical treatment in patients with ST elevation myocardial infarction (STEMI). However, oral antiplatelet agents, such as prasugrel or ticagrelor, are characterized by slow gastrointestinal drug absorption in the acute phase...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ahj.2020.03.005

データ提供：米国国立医学図書館（NLM）

The COMPARE CRUSH Trial: Examining the Impact of Crushed Prasugrel Tablets in STEMI

The field of cardiology is constantly seeking ways to improve the treatment of ST elevation myocardial infarction (STEMI), a life-threatening condition requiring prompt intervention. This research focuses on the potential benefits of administering crushed prasugrel tablets in STEMI patients undergoing primary percutaneous coronary intervention (PCI). The authors present the rationale and design of the COMPARE CRUSH trial, which aims to investigate the clinical implications of crushing prasugrel tablets in terms of drug absorption, platelet inhibition, and overall patient outcomes.

A Novel Approach to STEMI Treatment: Crushing Prasugrel Tablets

The COMPARE CRUSH trial represents a novel approach to STEMI treatment, exploring the potential of crushing prasugrel tablets to improve drug absorption and achieve earlier antiplatelet effects. The trial aims to address the limitations of conventional oral administration of antiplatelet agents, which can lead to delayed platelet inhibition in the acute phase of STEMI. This research has the potential to revolutionize STEMI treatment, providing a more effective and timely strategy for managing this critical condition.

Improving Outcomes in STEMI: The Promise of Crushed Prasugrel

This research has the potential to significantly improve outcomes in STEMI patients. If the COMPARE CRUSH trial demonstrates the efficacy of crushed prasugrel tablets, it could lead to faster and more effective platelet inhibition, potentially reducing the risk of complications and improving overall patient survival. This study underscores the importance of continuous innovation in cardiology to optimize treatment strategies and improve outcomes for those experiencing life-threatening heart conditions.

Dr.Camel's Conclusion

This research, much like a camel navigating a treacherous desert path, presents a new and innovative approach to managing STEMI. The COMPARE CRUSH trial holds the promise of improving treatment outcomes for STEMI patients by exploring the potential benefits of crushing prasugrel tablets. Just as a camel adapts to the harsh desert environment, healthcare professionals must remain adaptable in their efforts to improve patient care, embracing new approaches to address the challenges of cardiovascular disease.

Date :
  1. Date Completed 2020-07-16
  2. Date Revised 2020-07-16
Further Info :

Pubmed ID

32272255

DOI: Digital Object Identifier

10.1016/j.ahj.2020.03.005

Related Literature

Article Analysis
・Effects of prasugrel・Effects of protriptyline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.